ArticleeLife2023
Scaling of an antibody validation procedure enables quantification of antibody performance in major research applications.
Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 53 citations in OpenAlex.
- Screening molecular recognition element-based SWCNT optical sensors for the inflammatory cytokine TNF-α.Biosensors & bioelectronics · 2026Article
- Better antibodies, better science.PLoS biology · 2026Article
- Inadequate antibody validation places substantial numbers of animal and human tissue samples at risk of waste.PLoS biology · 2026Article
- Actionable solutions to address antibody validation failures.PLoS biology · 2026Article
- Reproducibility in biomedical research.Nature medicine · 2026Review
- Article
- Submolecular modulation of PIEZO1 mechanotransduction with wireless tailor-made nanoswitches.Bioactive materials · 2026Article
- AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins.Nature communications · 2026Article
- Technologies to measure and modulate protein subcellular localization.Nature reviews. Molecular cell biology · 2026Review
- Science sleuths uncover more than 100 suspicious images in Thermo Fisher antibody catalogue.Nature · 2026Article
- Phage Display Derived Antibodies Against Antimicrobial Peptide FsPDF2 Reveal Stress Response in European Beech.Plant biotechnology journal · 2026Article
- Screening Molecular Recognition Element-Based SWCNT Optical Sensors for the Inflammatory Cytokine TNF-α.bioRxiv : the preprint server for biology · 2026Article
- A guide to selecting high-performing renewable antibodies for KIF5A (Q12840) across western blot, immunoprecipitation, and immunofluorescence.F1000Research · 2026Article
- A guide to selecting high-performing antibodies for Alpha-1-antitrypsin (UniProt ID: P01009) for use in western blot, immunoprecipitation and flow cytometry.F1000Research · 2026Article
- A guide to selecting high-performing antibodies for DJ-1 (F1000Research · 2026Article
- Validation of LILR antibody specificities and development of LILRA3-specific antibodies.Frontiers in immunology · 2026Article
- A guide to selecting high-performing antibodies for Prosaposin (UniProt ID: P07602) for use in western blot and immunoprecipitation.F1000Research · 2026Article
- A guide to selecting high-performing antibodies for Netrin-1 (UniProt ID: O95631) for use in western blot and immunoprecipitation.F1000Research · 2026Article
- A guide to selecting high-performing antibodies for MMP7 (UniProt ID: P09237) for use in western blot and immunoprecipitation.F1000Research · 2026Article
- A guide to selecting high-performing antibodies for ARID2 (UniProt ID: Q68CP9) for use in western blot, immunoprecipitation, and immunofluorescence.F1000Research · 2026Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
19 authors at 5 institutions in 3 countries.
Funding
Abstract
Antibodies are critical reagents to detect and characterize proteins. It is commonly understood that many commercial antibodies do not recognize their intended targets, but information on the scope of the problem remains largely anecdotal, and as such, feasibility of the goal of at least one potent and specific antibody targeting each protein in a proteome cannot be assessed. Focusing on antibodies for human proteins, we have scaled a standardized characterization approach using parental and knockout cell lines (Laflamme et al., 2019) to assess the performance of 614 commercial antibodies for 65 neuroscience-related proteins. Side-by-side comparisons of all antibodies against each target, obtained from multiple commercial partners, have demonstrated that: (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.